Biocytogen’s YH008 Greater China Licensee Chipscre...

Beijing, China, January 5, 2024 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) partner Chipscreen NewWay Biosciences (“Chipscreen NewWay”) achieved first-patient-in for a phase I clinical trial evaluating a PD-1 x CD40 b...

Biocytogen/Eucure Biopharma to Present Complete Cl...

Beijing, China, Oct 16, 2023 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), will attend and present a poster at the ESMO Congress 2023, taking place in Madrid, Spain from O...

Biocytogen’s Subsidiary Eucure Biopharma and Chips...

BEIJING, China, February 27, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive l...

Biocytogen Announces FDA Clearance of IND Applicat...

BEIJING, China, December 19, 2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an internally dev...

First Patient Dosed in Phase 1/2 Trial Evaluating...

Beijing, China and San Diego, CA, November 22, 2022 - Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON...

ucure Biopharma, a Subsidiary of Biocytogen, Annou...

YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential. YH003 in combination with PD-1 are being dosed in phase II multi-regional clinical trials sponsored by Eucure Biopharma for pancreatic cancer and mela...